Having trouble accessing articles? Reset your cache.

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced plans to raise a minimum of CHF25 million ($24 million) in a private round prior to reverse merging with Arpida Ltd.

The HBM BioVentures and BioCapital funds are poised to return a substantial amount of cash to their investors following the sale of portfolio companies EsbaTech AG and Brahms AG. According to HBM CEO Andreas Wicki, the

Read the full 911 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers